An 11-year nationwide registry-linkage study of opioid maintenance treatment in pregnancy in Norway

Forfattere

  • Ingvild Odsbu Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway
  • Milada Mahic Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway
  • Svetlana Skurtveit Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway, Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway
  • Ingunn-Olea Lund Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway
  • Marte Handal Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway, First Faculty of Medicine, Charles University, Praha, Czech Republic

DOI:

https://doi.org/10.5324/nje.v29i1-2.4047

Sammendrag

Aim: We aimed to describe opioid maintenance treatment (OMT) to pregnant women in Norway and study the
background characteristics of the pregnant women compared to the general population of pregnant women and
to a previous clinical cohort study of OMT in pregnancy.
Methods: Population-based cohort study with linked data from the Norwegian Medical Birth Registry, the
Norwegian Prescription Database, the Norwegian Patient Registry, and Statistics Norway. The study population
consisted of women giving birth between 2005-2015 in Norway. We defined OMT pregnancies as pregnancies
where the woman was dispensed OMT medications (methadone, buprenorphine, or buprenorphine/
naloxone) at least once during pregnancy.
Results: The study population consisted of 420,808 women with 645,440 pregnancies ending in a live birth in
Norway in 2005-2015 (the general pregnant population). Of these, 261 women (0.6‰) had altogether 306
OMT pregnancies. The mean number of pregnancies was 28 OMT pregnancies per year and quite stable during
the study period. Women with OMT pregnancies were older, smoked tobacco more frequently, had lower
education, and fewer of them had a partner, compared to the general population of pregnant women. In most
pregnancies, the women were treated with buprenorphine (n=183 (59.8%)), while in 120 (39.2%) pregnancies,
the woman received methadone. From 2008, buprenorphine replaced methadone as the most frequently used
drug. In only 38 (12.4%) pregnancies, OMT treatment was initiated in pregnancy. In 201 (66%) pregnancies,
the woman used OMT medications in all trimesters. For these women, the mean amount of dispensed drug was
3.4 DDD/day (85 mg/day) in pregnancy for methadone and 1.9 DDD/day (15.2 mg/day) for buprenorphine.
Conclusion: The number of OMT pregnancies per year has been low and stable in the period 2005-2015.
Following Norwegian recommendations, there has been a shift from treatment with methadone towards
buprenorphine. The women receiving OMT during pregnancy had more risk factors for adverse outcomes than
the general pregnant population but were quite similar to the previous clinical cohort.

Downloads

Download data is not yet available.

Nedlastinger

Publisert

2021-08-16